U.S. Markets open in 4 hrs 51 mins
  • S&P Futures

    3,595.50
    -6.00 (-0.17%)
     
  • Dow Futures

    28,838.00
    +37.00 (+0.13%)
     
  • Nasdaq Futures

    10,964.50
    -71.00 (-0.64%)
     
  • Russell 2000 Futures

    1,673.30
    +3.50 (+0.21%)
     
  • Crude Oil

    83.11
    +3.62 (+4.55%)
     
  • Gold

    1,673.50
    +1.50 (+0.09%)
     
  • Silver

    19.43
    +0.39 (+2.05%)
     
  • EUR/USD

    0.9820
    +0.0019 (+0.1964%)
     
  • 10-Yr Bond

    3.8040
    0.0000 (0.00%)
     
  • Vix

    32.80
    +0.96 (+3.02%)
     
  • GBP/USD

    1.1223
    +0.0057 (+0.5106%)
     
  • USD/JPY

    145.0260
    +0.2970 (+0.2052%)
     
  • BTC-USD

    19,211.16
    -70.85 (-0.37%)
     
  • CMC Crypto 200

    436.28
    -7.15 (-1.61%)
     
  • FTSE 100

    6,833.89
    -59.92 (-0.87%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder

Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.

"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys" with early, active Cerebral Adrenoleukodystrophy (CALD), the company said in a statement, saying CALD is a "devastating and fatal neurodegenerative disease."

(Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)